PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50%

J. Dolezal,G. Lo Russo,C. Proto,A. Prelaj,M. Ganzinelli,R. Mortarini,V. Torri,R. Ferarra,L. Agnelli,S. Brich,M.C. Garassino

Journal of Thoracic Oncology（2023）

引用 0|浏览10

暂无评分

摘要

Efficacy of pembrolizumab in PD-L1<50% has been reported without no reliable biomarkers. The aim of this trial was to identify potential new immune biomarkers associated with PFS in NSCLC patients with PD-L1<50% treated with first-line pembrolizumab.

查看译文

关键词

pembrolizumab,advanced nsclc patients,biomarkers,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1&gt;50%

PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50%